Mineralys Therapeutics, Inc. MLYS Change in accrued investment income
Change in accrued investment income at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet.
The official record: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mineralys Therapeutics, Inc.'s change in accrued investment income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mineralys Therapeutics, Inc.'s change in accrued investment income?
- Mineralys Therapeutics, Inc. (MLYS) reported change in accrued investment income of -$289K in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s change in accrued investment income changed year-over-year?
- Mineralys Therapeutics, Inc.'s change in accrued investment income decreased by 455.8% year-over-year, from -$52K to -$289K.
- What does change in accrued investment income mean?
- This metric measures the net change in interest or dividends earned on investment assets that have been recognized as income but not yet received in cash. A positive change indicates an increase in receivables, representing a temporary drag on operating cash flow. Monitoring this helps analysts understand the timing differences between accounting revenue recognition and actual cash collection from treasury activities.